



SolAeroMed Inc.  
Unit 2, Research Transition Facility  
3535 Research Road N.W.  
Calgary, Alberta, Canada T2L 2K8

Email: [info@solaeromed.com](mailto:info@solaeromed.com)

## SolAeroMed Shareholder Newsletter August 4, 2017

Hello SolAeroMed Shareholders

I write to invite you to the SolAeroMed AGM on Thursday Sept 7 2017 from 4-6pm at our offices 3535 Research Rd NW Calgary. While we encourage shareholders to attend in person, and we will also arrange for remote participation via phone or www.


We will organize the Sept 7<sup>th</sup> meeting in 2 parts. The 1<sup>st</sup> half (4-5pm) will contain our formal AGM, and will include presentations of F2017 financials, confirmation of Board, etc. After the formal AGM, and after a brief break we will conduct more informal meeting in which we'll share an informative update on our progress, outline our future plans, and hold a Q&A session.

By way of update, we are pleased to share news around recent progress, technology development and business development:

1. Our SolAeroMed team travelled down to San Diego June 18-22, 2017 to promote our technology and explore partnerships at the biotech RESI and BIO meetings. Our presence at these meetings was facilitated and supported by the Canadian Consulate and this affiliation helped raise our profile amongst the many other 30,000+ delegates. Follow up discussions with potential partners continues.
2. SolAeroMed has entered into a formal arrangement with Primary Capital LLC to progress S1226 development through a \$2M-\$5M capital raise to complete an envisioned S1226 registration clinical trial. [Primary Capital, LLC](#) is a full service investment banking firm registered with Securities and Exchange Commission (SEC), and a member of both the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC)
3. Our SolAeroMed team has advanced detailed plans to submit our next clinical trial application pending introduction of funding.
4. In July SolAeroMed has negotiated and executed a formal arrangement with a Dutch based company, [Okklo Life Sciences](#), to supply novel cyclodextrin candidates to advance our S1229 research program.
5. Dr Mustafa Al Saiedy has been working for SolAeroMed full time since September 2016 to screen and assess novel S1229 molecules. Mustafa completed

his PhD in this area, and we are benefitting from his experience and laboratory abilities.

6. We received news in June that our S1229 patent has now been granted in Japan.
7. We have now completed a formal collaboration with Melbourne based Hydrix who have worked with our SAIT engineers to refine design options of our S1226 portable device. The final report is completed and describes a simple and elegant solution for the portable delivery of S1226 (see schematic) which has minimum moving parts, no electronics, and a relatively low expected cost of production.
8. We have extended national filing of our S1226 portable device patent beyond the USA. Filing countries now include: USA, Canada, Mexico, Europe, China, Australia, Israel, and Korea.
9. We continue to prepare manuscripts for journal publication and interested shareholders can [peruse updated articles](#) on our SolAeroMed web site.



At our Sept 7<sup>th</sup> meeting we will review select aspects of this work, along with an informal outline of our future plans and Q&A.

We will continue to keep shareholders informed through newsletters and our web site. We greatly value interaction with shareholders and invite you to contact me directly if you have questions or wish to share concerns

We look forward to seeing you for our AGM on Sept 7 and hope you can make the meeting in person. 2017 promises to be a most interesting year for the development of SolAeroMed.

Sincerely

Dr John Dennis, PhD  
CEO SolAeroMed Inc

[www.solaeromed.com](http://www.solaeromed.com)